Difference between revisions of "Anagrelide (Agrylin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.<ref name="insert">[http://www.shire.com/shireplc/dlibrary/documents/AgrylinUSPIAug2009.pdf Anagrelide (Agrylin) package insert]</ref><ref>[[Media:Anagrelide.pdf | Anagrelide (Agrylin) package insert (locally hosted backup)]]</ref> | Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.<ref name="insert">[http://www.shire.com/shireplc/dlibrary/documents/AgrylinUSPIAug2009.pdf Anagrelide (Agrylin) package insert]</ref><ref>[[Media:Anagrelide.pdf | Anagrelide (Agrylin) package insert (locally hosted backup)]]</ref> | ||
| Line 16: | Line 14: | ||
*[http://chemocare.com/chemotherapy/drug-info/anagrelide.aspx Anagrelide (Agrylin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/anagrelide.aspx Anagrelide (Agrylin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/anagrelide.aspx Anagrelide (Agrylin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/anagrelide.aspx Anagrelide (Agrylin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Agrylin, Xagrid | ||
==References== | ==References== | ||
| Line 21: | Line 22: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
[[Category:Phosphodiesterase inhibitors]] | [[Category:Phosphodiesterase inhibitors]] | ||
Revision as of 18:39, 29 October 2017
General information
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.[1][2]
Route: PO
Extravasation: n/a
- Example of usage: Anagrelide (Agrylin) 0.5 mg PO 4 times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Anagrelide (Agrylin) patient drug information (Chemocare)[3]
- Anagrelide (Agrylin) patient drug information (UpToDate)[4]
Also known as
- Brand names: Agrylin, Xagrid